GSK and CureVac patent dispute

GSK to Receive $320 Million as BioNTech and Pfizer Settle mRNA Patent Dispute with CureVac

One of the biggest developments in the ongoing mRNA patent dispute has arrived—GSK will receive $320 million following a settlement between the BioNTech, CureVac, and Pfizer dispute. The agreement, reached after BioNTech and Pfizer chose to end a high-profile legal battle with the German biotech CureVac, closes a multi-year dispute over mRNA vaccine technology. The […]